Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma

BACKGROUND: Monoclonal antibodies (mAbs) targeting negative regulators, or checkpoint molecules (e.g. PD1/PD-L1 & CTLA4), of anti-tumoural T cells have demonstrated clinical efficacy in treating several neoplastic diseases. While many patients enjoy remarkable responses to checkpoint inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijayakumar, Gayathri, Palese, Peter, Goff, Peter H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945240/
https://www.ncbi.nlm.nih.gov/pubmed/31676387
http://dx.doi.org/10.1016/j.ebiom.2019.10.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945240/
https://www.ncbi.nlm.nih.gov/pubmed/31676387
http://dx.doi.org/10.1016/j.ebiom.2019.10.032

Ejemplares similares